July 27, 2017
Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update
1,460 active patients at June 30, 2017, an increase of 64 percent from June 30, 2016, and 15 percent from March 31, 2017 Second quarter 2017 net revenues of $38.4 million, reflecting 114 percent growth versus second quarter 2016 and 10 percent growth versus first quarter 2017… Read More
learn more
July 24, 2017
Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma
This trial is the first to study Optune in combination with an investigational drug ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today a new arm for a phase 1b study to evaluate the safety of marizomib and temozolomide in combination with Optune, Novocure’s Tumor Treating Fields (TTFields)… Read More
learn more
July 12, 2017
Novocure’s Optune® Now Available at More Than 600 Cancer Treatment Centers in the U.S.
Company broadens geographic reach of Optune in community setting, making therapy more accessible to patients Internationally, GBM patients can access Optune at an additional 350 medical institutions ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ: NVCR) announced today that physicians at more than 600 cancer treatment centers… Read More
learn more
July 11, 2017
Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society
Three oral presentations underscore Novocure’s commitment to further understanding the physical application of Tumor Treating Fields to enhance efficacy ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that three oral presentations on Tumor Treating Fields (TTFields) will be given at the 39th Annual International Conference of… Read More
learn more
June 30, 2017
Novocure to Report Second Quarter 2017 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2017 on Thursday, July 27, 2017, before the U.S.-based financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and… Read More
learn more
June 30, 2017
Novocure to Report Second Quarter 2017 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2017 on Thursday, July 27, 2017, before the U.S.-based financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and… Read More
learn more
June 28, 2017
Novocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer
A phase 3 pivotal trial – PANOVA-3 – will test the efficacy of TTFields with gemcitabine and nab-paclitaxel as a front-line treatment of locally advanced pancreatic cancer ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the company will present three abstracts studying Tumor Treating Fields… Read More
learn more
June 28, 2017
Novocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer
A phase 3 pivotal trial – PANOVA-3 – will test the efficacy of TTFields with gemcitabine and nab-paclitaxel as a front-line treatment of locally advanced pancreatic cancer ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the company will present three abstracts studying Tumor Treating Fields… Read More
learn more
June 13, 2017
Novocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the time of its presentation at the JMP Securities 2017 Life Sciences Conference has changed. The presentation at the conference is now scheduled for 10:30 am EDT on June 21, 2017, in New York. A live audio webcast… Read More
learn more
June 13, 2017
Novocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the time of its presentation at the JMP Securities 2017 Life Sciences Conference has changed. The presentation at the conference is now scheduled for 10:30 am EDT on June 21, 2017, in New York. A live audio webcast… Read More
learn more
